登录新浪财经APP 搜索【信披】查看更多考评等级 特别提示 重庆至信实业股份有限公司（以下简称"发行人"或"至信股份"）首次公开发行人民币普通股（Ａ股）并 在主板上市（以下简称"本次发行"）的申请已经上海证券交易所（以下简称"上交所"）上市审核委员会 审议通过，并已经中国证券监督管理委员会同意注册（证监许可〔２０２５〕２６０８号）。 申万宏源证券承销保荐有限责任公司（以下简称"申万宏源承销保荐"或"保荐人（主承销商）"）担任本 次发行的保荐人（主承销商）。西南证券股份有限公司（以下简称"西南证券"）担任本次发行的联席主 承销商（申万宏源承销保荐、西南证券合称"联席主承销商"）。 本次发行采用向参与战略配售的投资者定向配售（以下简称"战略配售"）、网下向符合条件的投资者询 价配售（以下简称"网下发行"）与网上向持有上海市场非限售Ａ股股份和非限售存托凭证市值的社会公 众投资者定价发行（以下简称"网上发行"）相结合的方式进行。 发行人与联席主承销商协商确定本次发行股份数量为５６，６６６，６６７股，占发行人发行后总股本 的２５．００％。本次发行初始战略配售数量为１１，３３３，３３３股，占本次发行数量的２０．０ ０％。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 保荐人（主承销商）：申万宏源证券承销保荐有限责任公司 联席主承销商：西南证券股份有限公司 特别提示 重庆至信实业股份有限公司（以下简称"发行人"或"至信股份"）首次公开发行人民币普通股（Ａ股）并 在主板上市（以下简称"本次发行"）的申请已经上海证券交易所（以下简称"上交所"）上市审核委员会 审议通过，并已经中国证券监督管理委员会同意注册（证监许可〔２０２５〕２６０８号）。 申万宏源证券承销保荐有限责任公司（以下简称"申万宏源承销保荐"或"保荐人（主承销商）"）担任本 次发行的保荐人（主承销商）。西南证券股份有限公司（以下简称"西南证券"）担任本次发行的联席主 承销商（申万宏源承销保荐、西南证券合称"联席主承销商"）。 本次发行采用向参与战略配售的投资者定向配售（以下简称"战略配售"）、网下向符合条件的投资者询 价配售（以下简称"网下发行"）与网上向持有上海市场非限售Ａ股股份和非限售存托凭证市值的社会公 众投资者定价发行（以下简称"网上发行"）相结合的方式进行。 发行人与联席主承销商协商确定本次发行股份数量为５６，６６６，６６７股，占发行人发行后总股本 的２５． ...

第1笔成交价格为96.92元，成交42.00万股，成交金额4,070.64万元，溢价率为-18.98%，买方营业部为西 南证券股份有限公司湖南分公司，卖方营业部为长城证券股份有限公司深圳分公司。 责任编辑：小浪快报 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 进一步统计，近3个月内该股累计发生3笔大宗交易，合计成交金额为6580.37万元。该股近5个交易日累 计上涨12.03%，主力资金合计净流出2.13亿元。 1月6日，国科微收涨11.10%，收盘价为119.63元，发生1笔大宗交易，合计成交量42万股，成交金额 4070.64万元。 ...

证券代码：600369 证券简称：西南证券 公告编号：临2026－001 西南证券股份有限公司 关于控股股东变更进展情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、本次控股股东变更的基本情况 2025 年 1 月，为深入贯彻落实党的二十届三中全会精神和重庆市委六届四 次五次六次全会精神及重庆市委、市政府关于突出主责主业强化核心功能整合优 化改革攻坚的工作部署，重庆渝富控股集团有限公司（以下简称渝富控股）通过 国有股权无偿划转受让重庆渝富资本运营集团有限公司（以下简称渝富资本）持 有的西南证券股份有限公司（以下简称公司）1,960,661,852 股股份，占公司总股 本的 29.51%（有关内容详见相关信息披露义务人于 2025 年 1 月 8 日在上海证券 交易所网站披露的《西南证券股份有限公司收购报告书》）。 本次收购完成后，渝富资本将不再持有公司股权，渝富控股将直接持有公司 1,960,661,852 股，占公司总股本的 29.51%，为公司控股股东。公司实际控制人 仍为重庆市国有资产监督管理委员会。 ...

重要提示 重庆至信实业股份有限公司（以下简称"至信股份"、"发行人"或"公司"）根据中国证券监督管理委员会 （以下简称"中国证监会"、"证监会"）颁布的《证券发行与承销管理办法》（证监会令〔第２２８ 号〕）（以下简称"《管理办法》"）、《首次公开发行股票注册管理办法》（证监会令〔第２０５ 号〕），上海证券交易所（以下简称"上交所"）颁布的《上海证券交易所首次公开发行证券发行与承销 业务实施细则（２０２５年修订）》（上证发〔２０２５〕４６号）（以下简称"《实施细则》"）、 《上海市场首次公开发行股票网上发行实施细则（２０２５年３月修订）》（上证发〔２０２５〕４３ 号）（以下简称"《网上发行实施细则》"）、《上海市场首次公开发行股票网下发行实施细则（２０２ ４年修订）》（上证发〔２０２４〕１１２号）（以下简称"《网下发行实施细则》"），中国证券业协 会颁布的《首次公开发行证券承销业务规则》（中证协发〔２０２３〕１８号）（以下简称"《承销业 务规则》"）以及《首次公开发行证券网下投资者管理规则》（中证协发〔２０２５〕５７号）（以下 简称"《网下投资者管理规则》"）和《首次公开发行证券网下投资者分类评价和管理指引》（ ...

Core Viewpoint - The AI medical market has significant potential, and iFlytek Medical Technology (02506) possesses a self-developed foundational large model, continuously enhancing its performance ceiling. The company is the most prominent player in the AI medical sector, benefiting from policy incentives and national projects, warranting ongoing attention [1]. Group 1: Shareholder Actions - Major shareholders, including the parent company iFlytek Co., Ltd. and key investors, voluntarily extended the lock-up period for their shares by one year until December 29, 2026, committing not to reduce their holdings during this period. As of the announcement date, these shareholders collectively held 52,758,395 H-shares, accounting for 68.25% of the total H-share capital and 72.86% of the total share capital [2]. - The voluntary extension of the lock-up period reflects the high recognition of the company's future development by key stakeholders, indirectly confirming the AI medical strategy and long-term growth potential. The high shareholding ratio of core shareholders helps stabilize market growth expectations and supports stock prices positively [3]. Group 2: Technological Advancements - In March 2025, the company launched the "iFlytek Spark Medical Model X1," the only medical deep reasoning model fully trained using domestically produced computing power. In real-world testing, its general auxiliary diagnosis accuracy reached 94.0%. By July 2025, the model's capabilities were upgraded, with the general auxiliary diagnosis accuracy improving to 95.0%, health consultation response rate to 91.5%, and major cardiovascular diagnosis accuracy to 91.2%. The model significantly outperformed international counterparts like OpenAI o3 and DeepSeek R1 in key medical tasks [4]. - The deep integration of the self-developed "Spark" model provides the company with a strong technological barrier, ensuring data security and autonomous control, which are critical for government and large public hospitals. This creates a significant entry advantage in the G-end and B-end markets [4]. Group 3: Market Outlook and Financial Projections - The integration of AI in healthcare is a clear direction for policy growth, with the company positioned to benefit as a leading player. Despite traditional medical IT investments facing pressure, the government emphasizes using AI to enhance grassroots diagnosis and optimize resource allocation, as outlined in various policy documents [5]. - Revenue forecasts for the company are projected at 930 million yuan, 1.21 billion yuan, and 1.58 billion yuan for 2025, 2026, and 2027, respectively, with corresponding price-to-sales ratios of 8.5x, 6.5x, and 5x [5].

Core Viewpoint - The AI medical market has significant potential, and iFlytek Medical Technology (02506) possesses a self-developed foundational model, continuously enhancing its performance ceiling. The company is the primary beneficiary of policy dividends and national projects in the AI medical sector, warranting ongoing attention [1]. Group 1: Shareholder Actions - Major shareholders, including the parent company iFlytek (002230) and key investors, voluntarily extended the lock-up period for their shares by one year until December 29, 2026, committing not to reduce their holdings during this period. As of the announcement date, these shareholders collectively held 52,758,395 H-shares, accounting for 68.25% of the total H-share capital and 72.86% of the total share capital [1][2]. Group 2: Technology and Product Development - In March 2025, the company launched the "iFlytek Spark Medical Model X1," the only medical deep reasoning model fully trained using domestically produced computing power. In real-world testing, its general auxiliary diagnosis accuracy reached 94.0%. By July 2025, the model's capabilities were upgraded, with the general auxiliary diagnosis accuracy improving to 95.0%, and other performance metrics also showing significant enhancements [3]. - The company’s deep reliance on its self-developed "Spark" model, based entirely on domestic computing power, provides two core advantages: strong market entry barriers due to data security and autonomy, especially in government and large public hospitals, and a feedback loop for continuous improvement of the model through accumulated data and application experience [3]. Group 3: Market and Policy Environment - The AI+medical sector is a clear direction for policy growth, with the company positioned to benefit significantly from this trend. Amid tightening fiscal and healthcare cost controls, traditional medical IT investments face pressure, while AI is recognized as a means to enhance grassroots diagnosis and optimize resource allocation, supported by various national policies [4]. - Revenue forecasts for the company are projected at 930 million yuan, 1.21 billion yuan, and 1.58 billion yuan for 2025-2027, with corresponding price-to-sales ratios of 8.5x, 6.5x, and 5x [4].

投资者可通过以下网址（ｈｔｔｐ：／／ｗｗｗ．ｓｓｅ．ｃｏｍ．ｃｎ／ｄｉｓｃｌｏｓｕｒｅ／ｌ ｉｓｔｅｄｉｎｆｏ／ｌｉｓｔｉｎｇ／、ｈｔｔｐ：／／ｗｗｗ．ｓｓｅ．ｃｏｍ．ｃｎ／ｉｐｏ／ ｈｏｍｅ／）查阅公告全文。 ■ 发行人和联席主承销商郑重提示广大投资者注意投资风险，理性投资，认真阅读本公告及在２０２６年 １月５日（Ｔ－１日）刊登在上交所网站（ｗｗｗ．ｓｓｅ．ｃｏｍ．ｃｎ）上的《重庆至信实业股份 有限公司首次公开发行股票并在主板上市投资风险特别公告》（以下简称"《投资风险特别公告》"）。 保荐人（主承销商）：申万宏源证券承销保荐有限责任公司 联席主承销商：西南证券股份有限公司 重要提示 重庆至信实业股份有限公司（以下简称"至信股份"、"发行人"或"公司"）根据中国证券监督管理委员会 （以下简称"中国证监会"、"证监会"）颁布的《证券发行与承销管理办法》（证监会令〔第２２８ 号〕）（以下简称"《管理办法》"）、《首次公开发行股票注册管理办法》（证监会令〔第２０５ 号〕），上海证券交易所（以下简称"上交所"）颁布的《上海证券交易所首次公开发行证券发行与承销 业务实施细则（２０２５年修订）》（上证发〔２０２５〕４６ ...

日前，中国银行间市场交易商协会（以下简称"交易商协会"）正式发布《关于2025年非金融企业债务融 资工具承销业务相关会员申请从事承销相关业务市场评价结果的公告》（下称《公告》），宣布新增一 批会员机构获得非金融企业债务融资工具承销业务资格。 本次扩容共纳入24家会员单位，涵盖多家银行机构，进一步丰富了市场参与主体，增强了金融体系对实 体经济特别是科技创新与地方经济的服务支撑能力。 三类承销商名单扩充 公告显示，交易商协会于2025年11月14日发布公告，启动了2025年非金融企业债务融资工具承销业务相 关会员申请从事承销相关业务市场评价工作。截至申请截止日2025年11月28日，共有37家会员提交了申 请材料，交易商协会秘书处依据市场评价标准组织审核工作，形成评价结果。本次资格调整新增三类业 务主体： 1．新增非金融企业债务融资工具一般主承销商8家，其中包括财通证券股份有限公司等机构。 | 序号 | 机构名称 | | --- | --- | | 1 | 财通证券股份有限公司 | | 2 | 第一创业证券承销保存有限责任公司 | | ﺗﻤﺎ | 华创证券有限责任公司 | | 4 | 华泰联合证券有限责任公司 | ...

Core Viewpoint - The announcement by the Interbank Market Dealers Association regarding the evaluation results for member applications to engage in underwriting non-financial corporate debt financing tools for 2025 highlights the approval of several institutions for relevant business qualifications [1][2]. Group 1: Institutions Approved - Institutions such as Huatai United Securities, JPMorgan Chase Bank (China), DBS Bank (China), Shanxi Securities, and Caitong Securities have received qualifications as general underwriters for non-financial corporate debt financing tools [1][2]. - Eight new members, including Caitong Securities and Huatai United Securities, have been designated as general underwriters for non-financial corporate debt financing tools [2]. - Bank of China International Securities has been approved as a special underwriter for technology innovation non-financial corporate debt financing tools [2]. Group 2: Application Process - The evaluation process for the 2025 underwriting business qualifications began on November 14, 2025, with a deadline for applications set for November 28, 2025, during which 37 members submitted their application materials [2]. - The evaluation results were approved by the fifth Bond Market Professional Committee and the fourth Board of Directors of the Association, and subsequently reported to the People's Bank of China [2]. Group 3: Regulatory Requirements - Underwriters are required to establish dedicated departments for underwriting business, appoint specialized personnel, and develop operational procedures, risk management, and internal control systems [4]. - Main underwriters must collaborate with independent main underwriters to conduct underwriting business and can independently engage in underwriting after gaining sufficient experience [4]. Group 4: Membership Classification - The Association classifies underwriters into main underwriters, underwriting members, and intending underwriting members, with main underwriters further divided into general and specialized categories [6][7]. - General main underwriters can engage in all categories of non-financial corporate debt financing tools, while specialized main underwriters can only handle specific categories [6].